Sunshine Guojian Pharmaceutical

Company snapshot

Sunshine Guojian Pharmaceutical maintains 165 tracked programs across Gout, Asthma, Type 2 Diabetes, Dermatitis, Atopic, Chronic Hepatitis C, Acne Vulgaris, Ankylosing Spondylitis, Advanced Malignant Tumors, Psoriasis, Sarcoma, Soft Tissue, Metastatic Colorectal Cancer, Advanced Solid Tumors. Momentum score: 25/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, p

• 14 approved product(s) across US/EU regulatory metadata.
• 165 active pipeline program(s) linked via ClinicalTrials.gov.
• 121 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Sunshine Guojian Pharmaceutical. Not investment advice.

• Congress May 15, 2026
  Bio-IT World Conference
• Presentation
  Results for SSGJ-707 (PD-1/VEGF bispecific antibody) in non-small cell lung cancer

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Amgen

  TA overlap score 39.2

• Peer + 0 momentum

  Bristol-Myers Squibb Australia

  TA overlap score 38.6

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Amneal Pharma Europe

  TA overlap score 23

• Peer + 0 momentum

  MedImmune

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Sunshine Guojian Pharmaceutical.

1. Jun 8, 2026 Clinical update

   SSGJ-611-PED-AD-Ib/II-01 — Phase 2

2. Jun 8, 2026 Clinical update

   TPO — Approved

3. Jun 8, 2026 Clinical update

   Sulforaphane — Approved

4. Jun 8, 2026 Clinical update

   SOF — Phase 3

5. Jun 8, 2026 Clinical update

   Recombinant Human Erythropoiesis Injection (CHO cell) — Phase 2

View all clinical trial activity →

• What is Sunshine Guojian Pharmaceutical?

  Sunshine Guojian Pharmaceutical is a pharma organization headquartered in FORT LAUDERDALE, FL, CN. Primary therapeutic focus areas include Gout, Asthma, Type 2 Diabetes, Dermatitis, Atopic, Chronic Hepatitis C. NovaPharmaNews links 165 clinical program(s), 11 drug profile(s), and

• Is Sunshine Guojian Pharmaceutical publicly traded?

  Sunshine Guojian Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sunshine Guojian Pharmaceutical develop or market?

  We link 80 drug profile(s) where Sunshine Guojian Pharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sunshine-biopharma#company-drugs.

• What are the latest developments for Sunshine Guojian Pharmaceutical?

  In the last 12 months our linked public records show 165 trial program update(s) and 5 US patent grant(s) tied to this profile.

• What therapeutic areas does Sunshine Guojian Pharmaceutical focus on?

  Sunshine Guojian Pharmaceutical focuses on Gout, Asthma, Type 2 Diabetes based on our analysis of their pipeline programs and drug development activities.